21 results about "Cholera toxin" patented technology

The invention provides a skin care composition containing stem cell extract as well as a preparation method and application of the skin care composition, and belongs to the technical field of cosmetics. The method comprises the following steps: mixing and culturing the extracted urine-derived stem cells and pilose antler stem cells in a DMEM culture medium added with epidermal growth factors, cholera toxin, penicillin, streptomycin, transferrin, IL-2 and IL-15, then separating a culture solution to obtain mixed exosomes, mixed stem cells and extracellular matrixes, preparing the mixed stem cells into stem cell lipidosome, and preparing the stem cell lipidosome. Embedding the stem cell extract and the mixed exosome into titanium dioxide / silicon dioxide microspheres, adding into an extracellular matrix, and uniformly dispersing to obtain the skin care composition containing the stem cell extract. The skin care composition containing the stem cell extract prepared by the invention can obviously prolong the preservation period of stem cells and exosomes and improve the repair and improvement of the stem cells and the exosomes on skin, and the prepared composition has better effects of resisting aging, whitening, promoting skin elasticity, resisting wrinkles and the like, and has a wide application prospect.

The invention discloses a culture medium for constructing a colorectal cancer peritoneal metastasis micro-tumor cell model and application of the culture medium. The invention relates to the technical field of biology, and provides a culture medium for culturing a micro-tumor model for colorectal cancer peritoneal metastasis. The invention discloses a cholera toxin immunopotentiator, which is composed of an antibacterial and antifungal agent three antibody, HEPES, GlutaMax, a human recombinant protein EGF, a human recombinant protein bFGF, a human recombinant protein HGF, a human recombinant protein Noggin, a human recombinant protein R-spondin 1, a human recombinant protein GDNF, SB202190, A83-01, Primocin, N-acetyl-L-cysteine, nicotinamide, an N2 additive, cholera toxin, B27, ITS-X, Y-27632, Galunissertib and a basal culture medium. The culture medium and the culture method disclosed by the invention can effectively improve the culture success rate of colorectal cancer peritoneal metastasis and focus combination.

The present disclosure provides for a synthetic immunogenic protein for use as an immuno-modulatory agent to enhance mammalian immune reactions towards conjugated protein or peptide containing antigens that are otherwise poorly immunogenic, including but not limited to self-antigens. The chimeric immunogenic proteins of the present disclosure can be used in the treatment of many illnesses, including but not limited to cancers, infectious disease, autoimmune disease, allergies and any clinical indication involving or affected by the immune response of a mammalian host.

The present invention provides a culture medium for primary ovarian cancer cells, an in vitro culture method, and applications thereof. The culture medium comprises an MST1 / 2 kinase inhibitor; at least one Rho protein kinase inhibitor selected from Y27632, fasudil, and H-1152; an insulin-transferrin-selenium supplement; insulin; prostaglandin E2; epidermal growth factor; gastrin; insulin-like growth factor-1; cholera toxin; amphiregulin; N2; and B27. Compared to existing culture methods, in vitro culture using the culture medium of the present invention has higher expansion efficiency. Culturing primary ovarian cancer cells using this culture medium can maintain the morphological structure and pathological characteristics of the primary tissue, thereby improving the success rate and survival rate of primary ovarian cancer cell culture.

The invention discloses a skincare stem cell exosome separation and extraction method, and relates to the technical field of biological medicine, the skincare stem cell exosome separation and extraction method comprises the following steps: S1, culture of mixed stem cells: unfreezing urine-derived stem cells and pilose antler stem cells, resuspending in an improved DMEM culture medium, and carrying out mixed culture to prepare a mixed culture solution; epidermal growth factors, cholera toxin, penicillin, streptomycin, transferrin, IL-2 and IL-15 are added into the improved DMEM culture medium; s2, pretreatment of the mixed culture solution: performing centrifugal treatment on the mixed culture solution, and separating to obtain a precipitate and a supernatant, the precipitate being mixed stem cells. The urine-derived stem cells and the pilose antler stem cells are subjected to mixed culture and matched with the improved culture medium containing IL-2, IL-15 and other components, so that the yield and biological activity of the exosome are remarkably improved, high purity and low impurity protein residue of the exosome are achieved by means of a complete purification process of multi-step centrifugation, ultrafiltration concentration and filter membrane filtration, and the yield of the exosome is improved. The skin allergy stimulation risk is effectively reduced.

The application provides a culture medium and a culture method of a gastric cancer organoid. The culture medium comprises an MST1 / 2 kinase inhibitor, a fibroblast growth factor 7, R-spondin 1, hydrocortisone, a B27 supplement, an N2 supplement, insulin, a dual regulatory protein, at least one Rho protein kinase inhibitor selected from Y27632, fasudil and H-1152, forskolin, gastrin, fetal bovine serum and cholera toxin. Compared with the existing culture method, the in-vitro culture using the culture medium has higher amplification efficiency; the culture of the gastric cancer organoid using the culture medium can maintain the morphological structure and pathological characteristics of the primary tissue, and improve the success rate and survival rate of the gastric cancer organoid culture.

The present invention relates to a growth medium, which does not include cholera toxin, for culturing cells, such as epithelial cells, in particular keratinocytes, use of the medium to grow cells, (for example epithelial cells, such as keratinocytes) and kits comprising the medium. Also provided is a method of generating human full thickness skin, fully human epidermis or fully human dermis involving culturing keratinocytes and feeder cells in said cell culture medium.

The application discloses a kind of serum-free epidermal melanocyte culture medium and its application, method includes by dissolving adenine, hepatocyte growth factor (HGF), glutamine, retinoic acid, vitamin E, nicotinic acid, sodium selenite, sodium hyaluronate and recombination human type XVII collagen are configured into initial culture medium;Preparation of melanocyte stimulating hormone, endothelin-3, transferrin, triiodothyronine, cholesterol, neuroregulin 1 (NRG1), 3-isobutyl-1-methyl purine (IBMX), dibutyryl cyclic adenosine monophosphate (db-cAMP), cholera toxin, hydrocortisone and recombination human insulin mother liquor;Step three: according to culture and concentration, a certain amount of mother liquor of step two is added to initial culture medium.The culture medium can effectively promote human epidermal melanocyte proliferation, melanin accumulation and help to promote human umbilical cord mesenchymal stem cells into human epidermal melanocyte, provide key advantage for obtaining functional melanocyte with high activity and therapeutic potential.

The application discloses a culture medium for constructing a gastric cancer ovary metastasis microtumor model and application. The application relates to the technical field of biotechnology, and provides a culture medium for constructing a gastric cancer ovary metastasis microtumor model, which is composed of three antibacterial and antifungal agents, HEPES, GlutaMax, human recombinant protein EGF, bFGF, HGF, FGF-10, Wnt-3a, Noggin, R-spondin 1, Follistatin, CHIR99021, SB202190, A83-01, Primocin, N-acetyl-L-cysteine, nicotinamide, N2 additives, cholera toxin, B27, ITS-X, Y-27632, gastrin, prostaglandin E2, beta-estradiol, progesterone, Galunisertib and a basic culture medium. The culture success rate of the gastric cancer ovary metastasis microtumor model is effectively improved.

The post-translational modification (PTM) and signaling molecule poly(ADP-ribose) (PAR) has an impact on diverse biological processes. PTM is regulated by a series of ADP-ribosyl glycohydrolases (PARG enzymes) that cleave polymers and / or liberate monomers from their protein targets. Disclosed herein is a substrate for monitoring PARG activity, TFMU-ADPr, which directly reports on total PAR hydrolase activity via release of a fluorophore; this substrate has excellent reactivity, generality, stability, and usability. A second substrate, TFMU-IDPr, selectively reports on PARG activity only from the enzyme ARH3. Use of these probes in whole-cell lysate experiments has revealed a mechanism by which ARH3 is inhibited by cholera toxin. TFMU-ADPr and TFMU-IDPr are versatile tools for assessing small-molecule inhibitors in vitro and probing the regulation of ADP-ribosyl catabolic enzymes.

The invention discloses a culture medium and a method for culturing digestive tract tumors by using a three-dimensional tumor chip technology. The culture medium is prepared from the following components: 5-10% v / v of FBS, 20-30% v / v of a Ham's F12 nutrient solution, 0.10-0.15 ng / mL of a recombinant human epidermal growth factor (EGF), 20-30 ng / mL of hydrocortisone, 0.05-0.15 nM of cholera toxin, 4-6 g / mL of insulin, 9-11 M of Y-27632 dihydrochloride, 10-30 [mu] g / mL of cefoperazone sodium, 5-15 [mu] g / mL of sulbactam sodium and the balance of DMEM (Dulbecco Modified Eagle Medium). The culture medium not only reduces the pollution rate, but also is high in cell activity and has an immune microenvironment similar to that of an original tissue, so that it is possible that an in-vitro 3D-TSCs culture method evaluates the drug sensitivity of immunotherapy drugs for clinical digestive tract tumors, and the culture medium has very high clinical application value and market potential.

The invention discloses a Klebsiella pneumoniae antigen epitope chimeric protein as well as preparation and application thereof, and relates to the fields of genetic engineering technologies, vaccines and diagnostic reagents. Amino acid sequences of Klebsiella pneumoniae outer membrane proteins OMPA, OMPN and CusC are analyzed through a computer, two B cell epitopes, one HTL epitope and one CTL epitope are respectively screened from the three outer membrane proteins, a cholera toxin subunit B (CTB) is used as an internal adjuvant, an EAAAK joint is used for connecting the amino acid sequence of the CTB and the B cell epitope of the OMPA, the B cell epitope and the HTL epitope are connected through a GPGPG flexible joint, and the CTL epitope and the CusC epitope are connected through a GMPG flexible joint. CTL inner epitopes are connected through an AAY connector to form a chimeric protein with multiple antigen fragments connected in series. A codon preferred by a pronucleus is selected, and a full-length gene of the chimeric protein is chemically synthesized. The chimeric protein is expressed and purified by using a gene engineering technology, and the chimeric protein has 312 amino acids in total length. The expressed chimeric protein can be used for developing vaccines, antibodies or antigen detection reagents.

This invention belongs to the field of regenerative medicine, specifically relating to a lacrimal gland organoid culture medium and a method for in vitro culture of lacrimal gland organoids. In one aspect, a lacrimal gland stem cell proliferation culture medium is provided, comprising: lacrimal gland stem cell basal culture medium, EGF, Wnt3a, FGF7, FGF10, RSP1, and Noggin; the lacrimal gland stem cell basal culture medium comprises: DMEM medium, F12 medium, L-glutamine, fetal bovine serum, hydrocortisone, cholera toxin, B27, penicillin, streptomycin, amphotericin B, and fasudil. In another aspect, a lacrimal gland stem cell differentiation culture medium is provided, comprising: lacrimal gland stem cell basal culture medium, EGF, Wnt3a, FGF7, FGF10, RSP1, Noggin, and BMP7. The lacrimal gland organoids constructed by this invention are larger in volume than those of existing technologies, possessing numerous branched ducts and vesicular acinar structures, extending radially and multidirectionally in a three-dimensional manner, forming a complex and regular three-dimensional tubular acinar network, and possessing secretory function.

The present application relates to a culture medium for liver cancer suspension organoid culture, comprising MST1 / 2 kinase inhibitor, Y27632, at least one cell culture additive selected from N2 and B27, SB202190, insulin, fibroblast growth factor 10, cholera toxin, ITS cell culture additive, hepatocyte growth factor, GlutaMAX, and non-essential amino acids. The present application also relates to a culture method of liver cancer suspension organoid and its use. By using the liver cancer suspension organoid culture medium of the present application, effective and rapid expansion of liver cancer cells can be achieved, the liver cancer cells obtained by expansion retain the pathological characteristics of the patient, the culture success rate and expansion rate of the liver cancer cells are improved, and research basis can be provided for personalized treatment of the patient.

The invention is directed to immunogenic compositions and vaccines, and methods for the manufacture and treatment and prevention of infections and, in particular, the preparation of immunogenic compositions and vaccines administered in conjunction with a detoxified cholera toxin as an adjuvant and a TLR agonist for oral administration, which may be encapsulated.

Some embodiments of the present disclosure relate to one or more compositions that upregulate the production of one or more sequences of mRNA. The sequences of mRNA may encode for translation of target biomolecules, thereby causing an increase in bioavailability of the target biomolecules within a subject that is administered the one or more compositions. In some embodiments of the present disclosure, the target biomolecules are modified Cholera toxin A and Cholera toxin B.

The present invention provides a culture medium for culturing primary gastric cancer cells, comprising an MST1 / 2 kinase inhibitor, a ROCK kinase inhibitor, at least one of a B27 additive and an N2 additive, basic fibroblast growth factor, CHIR99021, epidermal growth factor, an ITS cell culture additive, SB202190, dexamethasone, N-acetyl-L-cysteine, gastrin, A8301, oncostatin M, and cholera toxin. The present invention also relates to a culture method using the primary cell culture medium. The culture method uses the culture medium to culture primary gastric cancer cells on a culture vessel coated with extracellular matrix glue, thereby rapidly proliferating the primary cells.

Disclosed are a culture medium and a culture method for in vitro expansion of primary cells of intestinal cancer. The culture medium comprises an initial culture medium, a Rho protease inhibitor, an antibiotic, gastrin, A8301, a non-essential amino acid, cholera toxin, an insulin-like growth factor-1, nicotinamide, insulin, fetal bovine serum, and an additive selected from at least one of a B27 additive and an N2 additive. By using the culture medium, effective and rapid expansion of the primary cells of intestinal cancer can be achieved. The expanded cells maintain the pathological characteristics of patients, and the culture success rate and the cell expansion rate of the primary cells of intestinal cancer are improved, which provide a research foundation for personalized treatment of the patients.

To provide a cholera toxin production inhibitor and its use for realizing cholera treatment or cholera prevention by a different approach, which is not the conventional symptomatic treatment and antibacterial treatment. 【Solution means】A cholera toxin production inhibitor containing a compound represented by the following formula (1). TIFF2026058903000007.tif47164 (In formula (1), R 1 , R 2 , R 4 , R 5 , R 6 , and R 7 each independently represent a hydrogen atom, a hydroxyl group, or an alkoxy group having an alkyl group with 1 to 4 carbon atoms, and R 3 represents a hydrogen atom, a formyl group, or a carboxyl group. However, the case where all of R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R 7 are all hydrogen atoms is excluded.)

The present invention discloses a culture medium for constructing a colorectal cancer peritoneal metastasis microtumor cell model and its application. The present invention relates to the field of biotechnology and provides a culture medium for culturing a colorectal cancer peritoneal metastasis microtumor model, comprising antibacterial and antifungal agents, triple anti-antibiotics, HEPES, GlutaMax, human recombinant protein EGF, human recombinant protein bFGF, human recombinant protein HGF, human recombinant protein Noggin, human recombinant protein R-spondin 1, human recombinant protein GDNF, SB202190, A83-01, Primocin, N-acetyl-L-cysteine, nicotinamide, N2 additive, cholera toxin, B27, ITS-X, Y-27632, Galunisertib, and a basal culture medium. The culture medium and culture method disclosed in the present invention can effectively improve the culture success rate of colorectal cancer peritoneal metastasis and lesions.

The invention is directed to immunogenic compositions and vaccines, and methods for the manufacture and treatment and prevention of infections and, in particular, the preparation of immunogenic compositions and vaccines administered in conjunction with a detoxified cholera toxin as an adjuvant and a TLR agonist for oral administration, which may be encapsulated.